文献速递临床免疫分子诊断临床微生物

全自动罗氏Elecsys SARS-CoV-2抗原电化学发光免疫分析法诊断性能的汇总分析

Diagnostic performance of the fully automated Roche Elecsys SARS-CoV-2 antigen electrochemiluminescence immunoassay: a pooled analysis.
PubMed 文献 · Clin Chem Lab Med · 2022-02-03

本文对罗氏Elecsys SARS-CoV-2抗原电化学发光免疫分析法(ECLIA)与分子诊断参考方法比较的研究进行汇总分析,共纳入10项研究(n=6,095份鼻咽拭子)。汇总诊断灵敏度0.68(95%CI 0.66-0.70),特异度0.99(95%CI 0.99-0.99),AUC 0.958(95%CI 0.936-0.980);高病毒载量样本灵敏度0.95(95%CI 0.92-0.97)。

要点

  • 该抗原ECLIA对鼻咽拭子SARS-CoV-2感染的汇总特异度达0.99,灵敏度0.68。
  • 高病毒载量(Ct值<28-30)样本的汇总灵敏度为0.95,适合用于高病毒载量筛查。
  • 与分子检测的总体一致率为89.5%,kappa值为0.735。

核心结论

  • 全自动罗氏Elecsys SARS-CoV-2抗原ECLIA具有高诊断特异性和对高病毒载量鼻咽样本的良好诊断灵敏度,可作为大规模筛查及支持缩短隔离/检疫策略的可靠方法。

研究设计与样本

  • 在Scopus和Medline进行电子检索(截至2022年1月18日,无语言或日期限制),纳入将罗氏Elecsys SARS-CoV-2抗原ECLIA与参考分子诊断技术进行比较的研究。
  • 共识别11项研究,其中10项(n=6,095份鼻咽拭子)提供必要数据纳入汇总分析。

主要发现

  • 鼻咽样本的汇总诊断灵敏度为0.68(95%CI 0.66-0.70),特异度为0.99(95%CI 0.99-0.99),AUC为0.958(95%CI 0.936-0.980)。
  • 与参考分子检测的累积观察一致率为89.5%,kappa统计量为0.735(95%CI 0.716-0.754)。
  • 高病毒载量样本(Ct值<28-30)的汇总诊断灵敏度为0.95(95%CI 0.92-0.97)。

关键数值与推荐

  • 汇总诊断灵敏度0.68(95%CI 0.66-0.70),特异度0.99(95%CI 0.99-0.99),AUC 0.958(95%CI 0.936-0.980)。
  • 累积观察一致率89.5%,kappa 0.735(95%CI 0.716-0.754)。
  • 高病毒载量(Ct值<28-30)样本汇总灵敏度0.95(95%CI 0.92-0.97)。

临床怎么用

  • 该抗原ECLIA可用于大规模筛查,尤其适用于识别高病毒载量鼻咽样本。
  • 高特异度使其阳性结果可靠性较高,可支持缩短隔离和检疫策略。
  • 对低病毒载量样本灵敏度有限,阴性结果需结合分子检测确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Among the diagnostic tests that have recently become commercially available for diagnosing coronavirus disease 2019 (COVID-19), the fully-automated Roche Elecsys severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen electrochemiluminescence immunoassay (ECLIA) is one of the most widespread for its adaptability within a system of laboratory automation, rapidity and high-throughput. This article is aimed to provide the results of the first pooled analysis of its accuracy for diagnosing SARS-CoV-2 infections. CONTENT: We carried out an electronic search in Scopus and Medline, without language or date restrictions (i.e., up to January 18, 2022), to identify articles where the diagnostic performance of Roche Elecsys SARS-CoV-2 antigen ECLIA was compared with that of reference molecular diagnostic techniques. SUMMARY: Overall, 11 studies were identified, 10 of which (n=6,095 swabs) provided necessary data for inclusion in a pooled analysis. The pooled diagnostic sensitivity, specificity and area under the curve (AUC) in nasopharyngeal samples were 0.68 (95%CI, 0.66-0.70), 0.99 (95%CI, 0.99-0.99) and 0.958 (95%CI, 0.936-0.980), respectively. The cumulative observed agreement with reference molecular assays was 89.5% and the kappa statistic was 0.735 (95%CI, 0.716-0.754). The pooled diagnostic sensitivity in samples with high viral load (i.e., cycle threshold values <28-30) was 0.95 (95%CI, 0.92-0.97). OUTLOOK: The results of this pooled analysis confirm that the fully-automated Roche Elecsys SARS-CoV-2 antigen ECLIA has high diagnostic specificity and optimal diagnostic sensitivity for identifying nasopharyngeal samples with higher viral load, thus making it a reliable technique for mass screening and for supporting strategies based on shorten isolation and/or quarantine.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Lippi G, Henry BM, Adeli K, et al. Diagnostic performance of the fully automated Roche Elecsys SARS-CoV-2 antigen electrochemiluminescence immunoassay: a pooled analysis. Clin Chem Lab Med. 2022. PMID: 35114742. doi:10.1515/cclm-2022-0053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。